The Effect of Anti-Tumour Necrosis Factor alpha (Infliximab) on Sight-Threatening Uveitis in a Patient with Behçet’s Disease

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

“…Finally, when interferon itself fails to improve ocular symptoms, new molecules, such as anti-TNF-a seem to be appropriate. [25][26][27][28][29] Long term data and controlled studies are needed before drawing further conclusions about the firstline use of these compounds.…”

The Use of Biologic Agents in the Treatment of Ocular Manifestations of Behcet’s Disease

“…A teenage boy, previously treated unsuccessfully with a wide array of immunosuppressive medications and interferon-α, experienced a rapid resolution of visual disability when infliximab was initiated. 20 In a series of 12 patients treated in Italy, 11 had a decreased frequency of ocular relapses and all patients who were on corticosteroids prior to infliximab were able to reduce their daily dose of steroids. 21 Wechsler et al reported on 4 patients with refractory BD panuveitis, who all improved significantly when treated with infliximab.…”

“…One patient developed pyomyositis during infliximab therapy, necessitating a temporary suspension of treatment, one developed a perianal abscess, and another developed non-Hodgkin's lymphoma. 20,40,38 Active tuberculosis is the best-described complication of infliximab therapy and developed in some patients in these series. 31,21 One patient noted frequent urinary tract infections during infliximab treatment and many patients had upper respiratory infections.…”

Anti-TNF-α therapy for uveitis: Behçet and beyond

“…The volume of the literature is larger for infliximab but comprises mainly open, uncontrolled case series or single case reports, [12][13][14][15][16][17][18][19][20][21][22][23][24] the majority treating patients with Behçet's disease (BD). Despite the low hierarchy of evidence of these studies, most reports have shown a dramatic and lasting improvement in the vast majority of patients, and also allowed their normal immunosuppressive therapy to be tapered or discontinued.…”

“…13,14,16,17 Further case series, including patients with other types of uveitis, appeared, 15,[18][19][20] but three recent studies, in particular, require more detailed mention. Sfikakis et al 21 reported on the use of inflixmab in 25 patients with BD.…”